Frequently Asked Questions
If you have any additional questions, please email us here.
- To assess the immune response following COVID-19 infection or vaccination. Immune response to vaccination or infection tends to vary among people. It can be affected by age, genetic makeup, underlying disease, medications, etc. While vaccination confers protective immunity to most people, in some cases it does not, and it is vitally important to know in those cases so that appropriate precautions and lifestyle modifications can be made.
- To assess the need for a booster dose. As mentioned earlier, immune response to vaccine and/or infection varies among people. So, too, does the period of protection granted by the vaccine. As of now, it is unclear whether a booster shot is necessary for continuing protection, and if so, when to take it. Since the antibody levels are generally thought to be a good marker of protection following most vaccinations, it can provide an objective measure to help make the decision of whether and when to prescribe/take the booster shot.
- To make better decisions on rules for the workplace/public gatherings. In some institutions / public gatherings (like cruise ships or parks), vaccines are being mandated as a prerequisite for participation. However, for people who have already undergone COVID-19 infection, and are unwilling/unable to take the vaccine, a test for presence of significant levels of antibodies can help frame an alternative set of rules.
- To encourage vaccination in a more rational and humane manner. Some people have resistance to vaccination because they believe they have either high ‘natural immunity’ or that they have acquired immunity through close contact with infected people. It can be beneficial to help them assess the truth of these beliefs through an accurate and easy test. It is hoped that objective evidence, and comparison to others in the same demographic, can help dispel misconceptions that can lead to uninformed decision-making.
- To stratify risk for those with new COVID-19 infections. In patients with newly diagnosed COVID-19 infections who do not have prior immunity, antibody levels typically start to rise between 4-7 days after infection. However, for cases of infection in patients with prior vaccination/COVID-19 (‘breakthrough infection’), antibodies will likely be present at onset of infection. Since cases of breakthrough infection have much better prognosis than new infections, management of the disease can be objectively tailored.
Not quite. Immunity is a complex response involving many proteins (like antibodies and cytokines) and cells (immune cells like B and T lymphocytes). These components play different roles at different stages. However, antibody levels are a good marker of protection in many infections, and are regularly used to assess immune response for a number of other diseases. While research into the exact nature of COVID-19 is an ongoing, international effort, we do know that antibodies are generated as a result of infection and vaccination, and it is reasonable to assume that these antibodies seem to confer a material amount of immunity to most people.
Brevitest is actively developing additional Quantimmune™ tests which will assess the cellular immunity against COVID-19. You can learn more about our future plans on our Product Road Map page.
It depends. Clinical testing at our research facility seem to indicate that in most cases antibodies against the primary variant bind to some extent to the variants. The exact degree of this binding seems to vary by person, as well as by variant. For example, Patient A’s antibodies, generated through vaccination, may bind with 40% efficacy to the Delta variant, but with 20% efficacy to the Beta (South African). The corresponding values for Patient B can be 60% and 15%. Brevitest is developing tests to compare antibody binding with different variants, so that test takers can get a more complete picture of their immune status. You can learn more about our future plans on our Product Road Map page.
The WHO has created a standard sample using pooled serum from donors. The concentration of IgG in this sample has been fixed at 1000 BAU/ml. The standard is available to clinical laboratories around the world. Brevitest has calibrated its readout using the standard, thereby enabling the result to be reported in BAU/ml.
For now, Brevitest is only accepting direct payment from clients for its test. However, it may be possible to get the cost reimbursed through your insurance – please contact them to explore this possibility.
The choice to monitor your immune response through assessment of antibody levels is a decision you should make in consultation with your physician or health care professional. Antibody levels change with time, as does immunity. Patients may choose to track this change through regular testing. Since these changes typically take place over weeks and months, they can choose an appropriate testing schedule.
Yes! Brevitest offers two pricing plans, one that charges a flat fee for a single test and one that charges an annual fee and a lower, discounted rate for each test. Details are available on our Pricing Plans page, and you can contact us if there are additional questions.
Brevitest’s IgG assay is a laboratory-developed test (LDT) that has been clinically validated. The test population included people with prior infection and/or vaccination, and people with neither. The same population was also tested using an FDA approved IgG ELISA test that used venipuncture blood (Zeus test).
Brevitest’s test has perfect concordance (100% sensitivity, 100% specificity) when compared to the Zeus test (EUA approved).
No. Brevitest’s test is a laboratory developed test, or an LDT. It means that only personnel from Brevitest Laboratories can run the test.
While the test is always administered by Brevitest Laboratories at its CLIA laboratory, Brevitest is permitted to set up temporary testing locations. If you wish to set one up, please contact us.